Loue: Ivermectin and COVID-19 in Care Home: Case Report

Ivermectin and COVID-19 in Care Home: Case Report

Loue et al., J. Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202

Loue et al., Ivermectin and COVID-19 in Care Home: Case Report, J. Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202

Apr 2021 Source PDF

Twitter
Facebook

All Studies Meta

Small quasi-randomized (patient choice) study with 25 PCR+ patients in a nursing home offered ivermectin, of which 10 chose to be treated. The mean age was 83.5 in the treatment group and 81.8 in the control group. There was lower mortality and fewer serious cases with treatment.

Important missing comments or errors? Let us know.

risk of death, 70.0% lower, RR 0.30, p = 0.34, treatment 1 of 10 (10.0%), control 5 of 15 (33.3%), NNT 4.3.

risk of severe case, 55.0% lower, RR 0.45, p = 0.11, treatment 3 of 10 (30.0%), control 10 of 15 (66.7%), NNT 2.7.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Loue et al., 17 Apr 2021, retrospective quasi-randomized (patient choice), France, peer-reviewed, 2 authors, dosage 200μg/kg single dose.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Abstract: ISSN: 2474-3658 Loué and Fardeau. J Infect Dis Epidemiol 2021, 7:202 DOI: 10.23937/2474-3658/1510202 Volume 7 | Issue 4 Open Access Journal of Infectious Diseases and Epidemiology Case Report Ivermectin and COVID-19 in Care Home: Case Report Pierre Loué1 and Christine Fardeau2* Care Home EHPAD, Scarron, Fontenay aux Roses, France Department of Ophthalmology, Reference Center for Rare Diseases, La Pitié-Salpêtrière Hospital, ParisSorbonne University, France 1 2 Check for updates *Corresponding authors: Christine Fardeau, Department of Ophthalmology, Reference Center for Rare Diseases, La PitiéSalpêtrière Hospital, Paris-Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013 Paris, France

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit